Current And Emerging Technologies To Optimize mRNA Manufacturing

Source: Lonza

By Clemens Jakobi, Commercial Senior Director, Pharma and Biotech, Michał Domański, MSAT Lead mRNA Development, and Telmo Graça, Head of mRNA Process Development, Lonza


Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable promise, offering new opportunities for targeted treatment and flexible manufacturing, as demonstrated by the rapid development of mRNA-based COVID-19 vaccines. However, the field is still in its infancy, and the clinical potential of mRNA extends beyond vaccines. To date, there have been more than 348 clinical studies involving mRNA as an active ingredient or an enabler for cell and gene therapies such as CRISPR-Cas9 derived therapeutics.

Lonza has built considerable expertise in the production of mRNA, as both drug substance (DS) and drug product (DP). In this article, we discuss the benefits of using mRNA for vaccines and therapeutics while reviewing current and emerging mRNA production technologies. We address some technical, intellectual property (IP) and cost considerations a biopharma company will have to deal with, particularly when considering commercial production. Additionally, we illustrate how partnering with Lonza in the early clinical stages may help to access a reliable production workflow.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Advancing RNA